MYGN Stock Might Gain on The Lancet Study Backing Precise MRD

Myriad Genetics (MYGN) shares declined 2.7% following the publication of a study in The Lancet Oncology validating its Precise MRD test for clear-cell renal cell carcinoma, which demonstrated the test's ability to detect circulating tumor DNA levels associated with patient response and potentially enable treatment de-escalation. This immediate market reaction contrasts with the company's history of exceeding earnings estimates by an average of 210% over the past four quarters and the projected growth of the global MRD testing market to $4.50 billion by 2030, even as MYGN's stock has fallen 75.5% over the past year.

Analysis

Myriad Genetics (MYGN) has received significant clinical validation for its Oncology business, with a study in The Lancet Oncology demonstrating the performance of its Precise MRD test. The trial showed the test can identify clear-cell renal cell carcinoma patients who can remain on metastasis-directed therapy for a median of 54 months, double the 27-month median for those testing positive, thus enabling potential treatment de-escalation. This positions MYGN to compete in the global MRD testing market, projected to reach $4.50 billion by 2030. However, a stark disconnect exists between this positive clinical development and market sentiment. The company's shares fell 2.7% to $6.61 following the news, compounding a severe 75.5% decline over the past year, which sharply contrasts with the industry's 11.1% drop. This negative price action occurs despite a strong operational track record, where earnings have surpassed estimates by an average of 210% over the trailing four quarters, and another recent positive publication for its GeneSight Psychotropic test.

Key Decisions for Investors

• Investors should note the significant divergence between Myriad's positive clinical data and its severe stock underperformance, which may signal a potential value opportunity if the market begins to recognize the commercial potential of its validated tests.
• Monitor for evidence of commercial traction and revenue generation from the Precise MRD test, as its ability to capture share in the projected $4.50 billion MRD market could serve as a primary catalyst for reversing negative investor sentiment.
• Given the stock's 75.5% annual decline and the immediate negative reaction to positive news, a cautious approach is warranted; the current Zacks #3 (Hold) rating suggests holding existing positions may be more prudent than initiating new ones until a clear bottoming pattern or positive momentum is confirmed.